Recently, the market for anti-obesity treatments has grown drastically due to the release of glucagon-like peptide 1 receptor (GLP-1R) agonists, which can help reduce body weight and showcases antidiabetic effects [27]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.